Jasper Therapeutics, Inc.: Affinity Asset Advisors, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Affinity Asset Advisors, LLC disclosed a stake exceeding 5% in Jasper Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001011438-26-000690). The filing signals that the investment firm has crossed the threshold requiring public disclosure of its position in the clinical-stage biotech. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail on the size and intent of the position, and whether additional institutional holders follow with their own 13G filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Affinity Asset Advisors, LLC, Jasper Therapeutics, Inc.